The specter of generic rivalry has long loomed around copyright’s blockbuster drug, PDE5 Inhibitor, triggering questions about the prospects of similar drug portfolios. While initial years saw substantial profits, the patent lapse has opened the door for cheaper alternatives, possibly reducing earnings and posing a significant risk for stakeholde